The KD Pharma Group has acquired a 51% stake in Trigal Pharma

BIOGGIO, SWITZERLAND – October 4, 2021 – The KD Pharma Group has acquired a 51% stake in Trigal Pharma, a company specialized in clinical research, development and marketing of medical cannabinoids, such as Cannabidiol (CBD) in a highly-purified form.

“Trigal has successfully and profitably grown by being a first mover in the API market for cannabidiol (“CBD”), which is a natural fit with the KD Pharma Group,” said Oscar Groet, CEO of the KD Pharma Group.  “KD Pharma is a technology leader in lipid-based APIs, so adding cannabinoid leadership from Trigal into the KD Pharma family will help accelerate growth for both companies in this dynamic area.”

“We are pleased to form this strategic partnership with KD Pharma,” said Dr. Eberhard Pirich MD and CEO of Trigal Pharma, “because we have a shared vision that the market will demand more highly purified cannabinoids made under pharma GMP conditions in the future.”

The KD Pharma Group manufactures extracts and cannabinoid isolates at its facilities in Germany using its broad portfolio of lipid technologies, including novel technology for the extraction, concentration and isolation of cannabinoids. Trigal Pharma manufactures and distributes CBD API through the magistral preparations channel in Austria and Germany, including a partnership with a large Austrian pharmacy. The KD Pharma Group’s goal is to build the market leader in medical cannabinoids, a market that is largely untapped and has significant growth potential due to the pipeline of research in conditions ranging from neurological and psychotic disorders, treatment of substance use disorders and addiction, chronic pain conditions to cardiovascular disease and cancer.

Trigal Pharma will form an advisory board comprising of directors appointed by both companies immediately following the close of the transaction.  Other terms of the transaction were not disclosed.

About Trigal Pharma

Trigal Pharma is a pharmaceutical company, founded 2011 with more than 15 years of practical experience in clinical research and development, regulatory affairs and marketing of medical cannabinoids, particularly Cannabidiol. Since 2015 Cannabidiol capsules of different strengths as well as liquids for magisterial preparations have been developed in a very successful R&D cooperation with an Austrian pharmacy. Since more than four years in accordance with GMP standards CBD capsules have been produced for clinical trials in Australia and Europe, as well. In summary Trigal Pharma understands its role as a service company bringing scientific and marketing expertise in different sectors to globally operating manufacturers and producers of natural CBD and other cannabinoids.

About the KD Pharma Group SA

The KD Pharma Group is a CDMO that develops products in the pharmaceutical and nutraceutical space. It is also the worldwide leading producer of API for Omega-3 pharmaceuticals and has built a similar market-leading position in Omega-3 nutraceuticals, formulation and encapsulation services, with over 500 employees and a presence in the UK, Norway, Germany, Switzerland and the US. The KD Pharma Group employs state-of-the-art technology which is protected by numerous patents. Visit www.kdpharmagroup.com to learn more.

Pressemitteilungen

RAITH Group (“RAITH”), a leading developer and manufacturer of maskless nanofabrication systems and characterization solutions, announces the acquisition of Xnovo Technology ApS (“Xnovo”), an innovative technology development company specializing in advanced imaging methods and materials characterization. Xnovo was founded in 2012 as a spin-out from Denmark Technical University (DTU) and is headquartered in Køge, Denmark. […]

October 30, 2024 – capiton AG has successfully sold its portfolio company GRITEC TopCo GmbH (“GRITEC”) to the Viessmann Generations Group (“Viessmann”). GRITEC is Germany’s largest solution provider of turnkey technical buildings and stations for energy-, water- & industrial infrastructure. The company specializes in intelligent infrastructure and key components in the shift towards a decentralized […]

KD Pharma Group (“KD Pharma”), a leading CDMO in pharmaceutical and nutritional lipids, announces the acquisition of dsm-firmenich’s Marine Lipids business. As part of the transaction, dsm-firmenich will obtain a minority stake in KD Pharma and become co-shareholder alongside the capiton Omega continuation fund vehicles and other minority shareholders. The transaction will close in the […]

capiton portfolio company Dec Group is proud to announce the acquisition of the activities of Hainspitz-based BAUSCH Germany, a specialist for the design, manufacture, and supply of high-quality pharmaceutical aseptic fill-finish packaging solutions. With almost 25 years of experience, BAUSCH Germany has built a reputation as an innovative and reliable partner for pharmaceutical companies around […]

As of 29 February 2024, capiton portfolio company Betonbau presents itself under the new company name GRITEC. This is a significant step, underlining the company’s development to date, its current positioning, and its long-term strategic direction. Derived from “Grid” and “Technology”, the name reinforces the clear positioning as a full-service provider of system-relevant grid infrastructure […]

Raith, the leading manufacturer of precision technology for nanofabrication Instrumentation and part of capiton’s just recently, in January 2023 closed continuation vehicle Quantum, is pleased to announce the successful acquisition of NBF GmbH & Co. KG, a renowned supplier of precision technology, mechanical engineering, and system technology. The acquisition marks an important milestone in Raith’s […]

AlphaPet Ventures has further expanded its international brand platform with the acquisition of the Herrmann’s Manufaktur brand from Herrmann GmbH. Herrmann’s Manufaktur was launched as a leading organic premium pet food brand in Germany more than 17 years ago and enjoys great popularity among its loyal customers. The production of the Herrmann’s Manufaktur brand as […]

Successful Closing of Continuation Fund “capiton Quantum” for two leading German high-tech companies We are pleased to announce the closing of the €248m continuation fund “capiton Quantum”. capiton Quantum invested in Raith and AEMtec, two leading companies within the industrial technology space, originally acquired by capiton Fund V in 2016 and 2018, respectively. The continuation […]

capiton portfolio company Dec Group is proud to announce the acquisition of UK-Stoke-on-Trent based AWL, a specialist for the design, manufacturing and supply of continuous processing technologies and systems. Over the past decade, AWL has been at the forefront of continuous processing in the chemical, food and pharmaceutical industries by offering solutions from laboratory evaluation […]

capiton portfolio company Wundex is pleased to announce the acquisition of ELLIPSA, a wound care specialist with headquarters in Regensburg (Bavaria) and a second center of operations in Munich. In addition to the provision of wound care services and the wholesale supply of medical products, ELLIPSA has developed a proprietary digital education and training platform […]

capiton portfolio company Cedes is proud to announce the acquisition of the Vitector portfolio from Fraba, securing a leading position in the industrial door sensor market. As a global leader in elevator sensors, Cedes successfully applied its technology expertise and power of innovation to gain a foothold in the industrial door market, providing ultra-reliable safeguarding […]

Asyril SA, headquartered in Villaz-St-Pierre in Switzerland with subsidiaries in the US and Japan, is a market and technology leader in the flexible part feeder market. Its products are being used globally in assembly lines, facilitating process automation for a variety of industries.   Asyril’s product portfolio covers flexible feeding systems based on a patented […]